SynVivo recognized among “Top 10 Innovations of 2013” by The Scientist

HUNTSVILLE, Ala. December 4, 2013 - CFD Research Corporation developed SynVivo® microfluidic cell-based assay platform has been recognized as one of the "Top 10 Innovations of 2013" by The Scientist magazine. SynVivo enables faster, more efficient drug development by combining the control of in vitro testing with the realism of in vivo studies.

Read more: SynVivo recognized among “Top 10 Innovations of 2013” by The Scientist

CFDRC Developing Physiologically Realistic in vitro Tumor Microenvironment Platform

SynVivo-Tumor offers real-time analysis and visualization of drug delivery and cellular interactions and will be showcased at the December ASCB meeting in San Francisco.

HUNTSVILLE, Ala. December 10, 2012 - CFD Research Corporation has been awarded a $1.3M grant from the National Institutes of Health to develop their novel in vitro tumor model. SynVivo-Tumor replicates the tumor microenvironment with physiologically and morphologically realistic microvasculature including endothelial cell-lined leaky vessels and 3D solid tumors.

Read more: CFDRC Developing Physiologically Realistic in vitro Tumor Microenvironment Platform

Join Our Mailinglist